Perimenopause can make familiar cycles and body signals less predictable. One person may notice a clear change in periods or hot flashes; another may notice little at first. Hormones are part of this transition, but a hormone level or stage label cannot summarize every change—or explain every symptom.
Menopause is a point in time; the transition is a process
Menopause is the final menstrual period, identified retrospectively after 12 consecutive months without a period when another cause does not explain the change. Perimenopause describes the transition around that point, commonly including the first year after the final period. After menopause, a person is postmenopausal. Research frameworks such as STRAW+10 use menstrual-cycle changes as the main way to describe reproductive stages, with hormone measures serving as supporting information.
What changes in ovarian hormones are established
As the pool of ovarian follicles declines with age, ovulation and menstrual cycles become less regular for many people. The intervals between periods may first shorten and later become more variable, with skipped periods becoming more common. This is not a smooth, identical sequence for everyone, and cycles can still include ovulation during perimenopause.
Estradiol and follicle-stimulating hormone (FSH) change across this transition, but they do not move in a simple straight line. Estradiol can fluctuate from cycle to cycle and between people; FSH generally rises as ovarian activity declines, though it also varies. After menopause, estradiol is typically lower and FSH higher than during the reproductive years. A longitudinal SWAN analysis described average estradiol and FSH changes relative to the final menstrual period; a separate trajectory analysis identified multiple patterns in the cohort. These are group descriptions, not a single path to expect.
Progesterone is linked to ovulation, so cycles without ovulation can produce different progesterone patterns. A single blood test is only a measurement at one moment. It does not, by itself, map a person’s full transition or reliably forecast when a symptom will begin, how intense it will be, or when it will end.
Some effects are common; their timing and intensity vary
Hot flashes and night sweats are common during the transition, though not everyone has them. Lower estrogen exposure after menopause can also affect vaginal and urinary tissues for some people. These are established parts of menopause physiology, but the experience can range from minimal to disruptive, and symptoms do not arrive on one universal schedule.
Sleep, mood, and concentration may also change. They can overlap with night sweats, stress, life circumstances, existing sleep or health conditions, medications, and other influences. SWAN studies have found group-level associations and average patterns in sleep and cognitive testing; they do not show that one hormone level caused an individual’s experience. A reported “brain fog” is not itself a test result or diagnosis.
Weight and body composition can shift in midlife, but age, activity, sleep, health, medications, and many other factors are relevant alongside reproductive aging. The timing of a change around menopause does not establish that menopause or one hormone caused it. The same caution applies when several changes seem to arrive together.
What a population pattern cannot tell one person
Staging systems and cohort studies help researchers describe patterns across groups. They cannot tell an individual exactly what symptoms to expect, identify the cause of a particular change, or diagnose a hormone problem. Two people at the same reproductive stage can have different hormone measurements, symptoms, and health contexts. The Research Library’s Hormonal Transition section summarizes the study populations and limitations behind these findings.
Educational scope: This article provides general information about menopause research. It is not a diagnosis, an individualized assessment, or a treatment plan.
Source layer
The sources below describe reproductive-stage definitions, average hormone patterns, and selected midlife experiences. Consensus frameworks and observational cohorts answer different questions; none can diagnose or predict one person’s experience.
- Reproductive-aging staging consensus: Harlow SD, Gass M, Hall JE, et al. “Executive Summary of the Stages of Reproductive Aging Workshop +10: Addressing the Unfinished Agenda of Staging Reproductive Aging.” Menopause. 2012;19(4):387–395. STRAW+10 is an international consensus framework informed by available evidence, not a single-participant cohort. It places menstrual-cycle criteria at the center of reproductive staging and treats biomarkers as supporting measures. A staging framework describes population and research stages; it is not an individual diagnosis. PubMed, PMID 22343510.
- Longitudinal cohort study: Randolph JF Jr, Zheng H, Sowers MR, et al. “Change in follicle-stimulating hormone and estradiol across the menopausal transition: effect of age at the final menstrual period.” The Journal of Clinical Endocrinology & Metabolism. 2011;96(3):746–754. This SWAN analysis followed 1,215 women with a documented natural final menstrual period and examined how FSH and estradiol changed in relation to it. On average, FSH began rising several years before the final period, while mean estradiol began declining closer to it; the study measured cohort patterns, not an individual forecast. PubMed, PMID 21159842.
- Longitudinal hormone-trajectory analysis: Tepper PG, Randolph JF Jr, McConnell DS, et al. “Trajectory clustering of estradiol and follicle-stimulating hormone during the menopausal transition among women in the Study of Women’s Health Across the Nation (SWAN).” The Journal of Clinical Endocrinology & Metabolism. 2012;97(8):2872–2880. The analysis used repeated annual measures from women aged 42–52 across seven SWAN sites who later had a natural, dateable final menstrual period. It identified four estradiol and three FSH trajectories. The modeled groups describe variation in this cohort; they cannot diagnose or predict one individual’s course. PubMed, PMID 22659249.
- Longitudinal cohort study: Greendale GA, Huang MH, Wight RG, et al. “Effects of the menopause transition and hormone use on cognitive performance in midlife women.” Neurology. 2009;72(21):1850–1857. The analysis followed 2,362 SWAN participants with repeated measures of processing speed, verbal memory, and working memory over four years. It reported group-average patterns in selected test scores, not a diagnosis or a measure of dementia risk; observational findings do not establish that hormones caused a person’s cognitive experience. PubMed, PMID 19470968.
- Longitudinal cohort study: Kravitz HM, Zhao X, Bromberger JT, et al. “Sleep disturbance during the menopausal transition in a multi-ethnic community sample of women.” Sleep. 2008;31(7):979–990. This SWAN analysis followed 3,045 women aged 42–52 who were premenopausal or in early perimenopause at baseline, using repeated self-reports of sleep difficulty. Reported sleep symptoms were associated with transition characteristics, but the observational design cannot establish cause or predict one person’s sleep. PubMed, PMID 18652093.
- Public-health overview: World Health Organization. “Menopause.” This evidence-informed overview describes the menopause definition and a range of commonly reported symptoms. It is general health information rather than a study of one population, and it does not imply that every person experiences the same symptoms. WHO fact sheet.
For the studies already summarized by Eterna Femme, see the Research Library’s Hormonal Transition, Sleep, and Brain & Cognition sections.
Where to read next
Explore the Perimenopause Stages guide and the Menopause guide for more reproductive-aging context. For related experiences, continue with midlife sleep changes and what brain fog means. The Research Library’s Hormonal Transition section provides study populations and limitations.